Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.79 |
| ▸ | NPC1 | O15118 | 9/20 | 0.79 |
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26684066 | 0.90 | RAB9A (0.64) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL27940617 | 0.85 | AR (0.65) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL27727271 | 0.84 | NPC1 (0.74) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL2591810 | 0.82 | RAB9A (0.74) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL3097838 | 0.81 | ALDH1A1 (0.61) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL14852353 | 0.81 | RAB9A (0.76) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL1981263 | 0.78 | RAB9A (0.76) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL21114767 | 0.78 | RAB9A (0.76) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL3468742 | 0.77 | RAB9A (0.70) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL26828990 | 0.76 | NAAA (0.80) | RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2566860-B1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | RAB9A 579/4885NPC1 967/4885MAPT 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.